News
Scope 66 - Why do some people respond better to MS treatment...
A recent exploratory trial looking at the effect of the drug MIS416 on patients has f...
Scope 66 - Spectral cytometry taking off with second Aurora
The Malaghan Institute’s Hugh Green Cytometry Core team have had their hands full wit...
Scope 66 - Technology head makes international strides in cy...
Hugh Green Cytometry Fellow and head of research technology at the Malaghan Institute...
Scope 66 - David Downs: CAR T-cell recipient
David Downs, cancer survivor and self-declared ‘genetically modified organism’ recent...
Breast cancer research investigating vaccines to prevent rel...
The Malaghan Institute of Medical Research’s cancer immunotherapy team has been gi...
Allergy Today: Learning to live with allergens
This article originally appeared in the winter 2018 issue of Allergy Today. The Mal...
RNZ expert feature: harnessing the immune system to treat ca...
Speaking to Radio New Zealand presenter Jesse Mulligan, cancer immunotherapy programm...
Health Research Council backs Malaghan Institute to continue...
The Malaghan Institute of Medical Research’s outstanding programmes of scientific dis...
Malaghan Institute technology head making international stri...
In a New Zealand first, Hugh Green Flow Cytometry Fellow and head of research technol...
RadioLIVE: CAR-T cell therapy with Dr Rob Weinkove
Dr Rob Weinkove, clinical research fellow and clinical director of the CAR-T cell pro...